Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey

2019

KAYNAR, LEYLAGÜL

BOLAMAN, ALİ ZAHİT

Teke, Havva Uskudar

Atalay, Figen

ALTUNTAŞ, FEVZİ

Salihoglu, Ayse

BEKSAÇ, MERAL

Seval, Guldane Cengiz

PAYDAŞ, SEMRA

Tuglular, Tulin Firatli

ARSLAN, ÖNDER

GÖKER, HAKAN

Yurttas, Nurgul Ozgur

GÜRMAN, GÜNHAN

Cakar, Merih Kizil

Albayrak, Murat

Kabukcu, Sibel Hacioglu

YILMAZ, MEHMET

TOPÇUOĞLU, PERVİN

DEMİR, AHMET MUZAFFER

SÖNMEZ, MEHMET

PEHLİVAN, MUSTAFA